Ukwelapha i-HIV Nge-Triumeq

Iphilisi Yokuhlanganiswa Okuthandwayo Ngokwelashwa Kwokuqala

I-Triumeq iyi-once-daily, yokwakheka kwezidakamizwa ezilodwa-nsuku zonke ezisetshenziselwa ukwelashwa kwe-HIV. I-abacavir, lamivudine, ne-dolutegravir, i-Triumeq yamukelwa yi-US Food Administration and Drug Administration ngo-Agasti 2014 futhi yaqokwa njengomuthi okhethwayo ukwelashwa kokuqala ngomnyango wezeMpilo noHulumeni lwabantu.

Ukuhlolwa kokuqala kokwelapha

Ngaphambi kokuqala i-Triumeq, kufanele uhlolwe ukuze ubone ukuthi une-HLA-B * 5701 yokuguqula izakhi zofuzo.

Uma wenza kanjalo, ngeke ukwazi ukuthatha i-Triumeq njengoba ubeka ingozi yokuphendula okubalulekile kwe-abacavir hypersensitivity reaction .

I-Triumeq nayo ingasetshenziselwa abantu abanokukhubazeka kwezinso. Ukuze ugweme udoti oluhlobene nezidakamizwa, ukuhlolwa komsebenzi wezinso kumele kwenziwe ngaphambi kokuba ukwelashwa kunqunywe.

Isilinganiso Nokuphatha

I-Triumeq ihlelwe kuthebhulethi yomlomo ebizwa nge-abacavir 600mg, lamivudine 300mg, ne-dolutegravir 50mg. Izinga eliphakanyisiwe lilodwa iphilisi nsuku zonke, ethathwe noma ngaphandle kokudla. I-Triumeq iyithebhulethi ye-oblong e-off-white embossed ngakolunye uhlangothi "nge-572 Tri."

Imiphumela Ejwayelekile Ejwayelekile

I-Triumeq ibhekwa njengephephile lapho isetshenziselwa njengoba iqondiswe kepha ingabangela imiphumela emibi kwabanye. Iningi lalemiphumela emibi ibekezelela futhi ngokuvamile ixazulula eyedwa phakathi nesonto. Okuvamile (okwenzeka okungenani amaphesenti amabili wamacala) yi:

Ukuqhathaniswa nokusebenzisana

I-Tikosyn (i-dothelilidedi) , esetshenziselwa ukwelashwa kwe- arrhythmia (ukushaya kwenhliziyo okungavamile), iyaphikisana nokusetshenziswa ne-Triumeq.

Khuluma nodokotela wakho ngokufaka esikhundleni se-Triumeq noma i-Tikosyn uma udinga ukwelashwa kokubili isimo

Ukuze ugweme ukusebenzisana kwezidakamizwa, cebisa udokotela wakho uma uthatha noma yimiphi imithi elandelayo:

Izilinganiso zingadinga ukulungiswa noma ukufaka endaweni okutholakala.

Ukucabangela

Xhumana nodokotela wakho masinyane uma uthola ukusabela kokugula ngemuva kokuqala i-Triumeq. Funa ukunakekelwa kwezimo eziphuthumayo uma unomphefumulo ohambisane nomkhuhlane, ubuhlungu bomzimba noma ubuhlungu obuhlangene, izinkinga zokuphefumula, izinkinga zokuphefumula, noma ukuvuvukala kwamehlo, ubuso noma umlomo.

I-Triumeq kufanele ithathwe amahora amabili ngaphambi kokuqala noma amahora ayisithupha ngemuva kokuthatha i-aluminium noma i-magnesium-based based antacid noma i-laxative, ukwesekwa kwensimbi, i-calcium supplement, imithi ephucuziwe , noma i- sucralfate esetshenziselwa ukwelashwa kwezilonda ze-peptic.

Yazisa udokotela wakho noma yiziphi izimo zesibindi ongazithola ngaphambi kokuqala i-Triumeq. I-Triumeq ingabangela ukuwohloka kwezimpawu, ikakhulukazi kubantu abane- hepatitis B noma i- hepatitis C. Uma sekuqalwa ukwelashwa, ama-enzyme yesibindi kufanele ahlolwe njengengxenye yokuhlolwa kwegazi lomuntu.

> Imithombo:

> Ukuphathwa Kwezokudla Nezidakamizwa zase-US. "Amaphuzu avelele ekuchazeni ulwazi: amaphilisi e-TRIUMEQ (abacavir, dolutegravir, ne-lamivudine) okusetshenziselwa ngomlomo." I-Silver Spring, e-Maryland; Agasti 2014.

> Weller, S .; U-Chen, uS .; Borland, J .; et al. "I-bioequivalence ye-dolutegravir, abacavir, ne-lamivudine i-dose fixed-dose tablet kanye nomphumela wokudla." I-Journal of Immune Deficiency Deficiency Syndrome. Agasti 1.2014; 66 (4): 393-398. I-DOI: 10.1097 / QAI.0000000000000193.